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The failure of HIV-1 to escape at some cytotoxic T-lymphocyte (CTL) epitopes has generally been explained in terms of viral fitness costs or
ineffective or attenuated CTL responses. Relatively little attention has been paid to the evolutionary time required for escape mutants to be
detected. This time is significantly affected by selection, mutation rates, the presence of other advantageous mutations, and the effective
population size of HIV-1 in vivo (typically estimated to be ¨103 in chronically infected patients, though one study has estimated it to be ¨105).
Here, we use a forward simulator with experimentally estimated HIV-1 parameters to show that these delays can be substantial. For an effective
population size of 103, even highly advantageous mutants (s = 0.5) may not be detected for a couple of years in chronically infected patients, while
moderately advantageous escape mutants (s = 0.1) may not be detected for up to 10 years. Even with an effective population size of 105, a
moderately advantageous escape mutant (s = 0.1) may not be detected in the population within 2 years if it has to compete with other selectively
advantageous mutants. Stochastic evolutionary forces, therefore, in addition to viral fitness costs and ineffective or attenuated CTL responses,
must be taken into account when assessing the selection of CTL escape mutations.
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CD8+ cytotoxic T-lymphocyte (CTL) responses are associ-
ated with control of HIV-1 infection (Borrow et al., 1994; Koup
et al., 1994; Ogg et al., 1998), yet they rarely, if ever, clear the
infection. CTL escape, mediated by changes in reactive viral
epitopes or peptide processing, is an important mechanism by
which HIV-1 evades clearance (Borrow et al., 1997; Goulder et
al., 1997; Moore et al., 2002; Price et al., 1997; Wolinsky et al.,
1996). CTL escape mutants have been reported to appear within
a couple months after HIV-1 infection (Borrow et al., 1997; Cao
et al., 2003), indicating that CTL can be a strong selective force
influencing the evolution of HIV-1 in vivo. The failure to
observe escape mutations at some epitopes has led to the
conclusions that certain CTL responses do not exert significant
selective pressure (Brander et al., 1998; Hay et al., 1999;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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and that escape mutants have lower fitness (Goulder and
Watkins, 2004; Leslie et al., 2005; Yang et al., 2003). However,
other events that may delay the time to the appearance of
selectively advantageous mutants are rarely mentioned.
Here, we used a forward simulator that makes standard
population genetics assumptions (e.g., constant population size,
no subdivision, constant selection, discrete generations, and no
recombination) to estimate the time required for an advanta-
geous CTL escape mutant to be observed. Using this model, we
demonstrate the contribution of stochastic mutational effects
(Frost et al., 2000; Rouzine and Coffin, 1999), genetic drift
(Brown, 1997), selection strength, sampling limitations, and
clonal interference (Gerrish and Lenski, 1998) to these delays.
We also discuss the effects of various violation of modeling
assumptions (e.g., fluctuating population sizes) on these delays.
For typical sampling schemes and experimentally estimated
HIV-1 parameters, we find that these delay times can be very
long.6) 140 – 146
www.e
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The time required for an advantageous HIV-1 mutant to reach
a given frequency
As illustrated in Fig. 1, advantageous mutations occur at
random. These mutants are either rapidly lost (due to drift) or
fixed. The time (tf) it takes for an advantageous mutant that
ultimately becomes fixed, Madv, to reach a given frequency ( f)
after infection will be the sum of the time for its occurrence,
tadv, and the time for it to reach f afterwards.
The time required for an advantageous mutant to reach a
given frequency, tf, is a complex function of the effective
population size (Ne), the advantageous mutation rate, and the
strength of selection. To estimate tf for an advantageous HIV-1
mutant, we conducted forward simulations (Liu et al., 2004)
with a constant population size, N = Ne, and HIV-1-specific
parameter values.
Although one study has reported Ne ¨ 10
5 for HIV-1 (Frost
et al., 2000; Rouzine and Coffin, 1999), most studies of
chronically infected untreated patients have estimated Ne to be
in the range of 103 to 5  103 (Brown, 1997; Seo et al., 2002;
Shriner et al., 2004b), including subsequent work that includes
the co-author that reported Ne ¨ 10
5 (Achaz et al., 2004). The
average nucleotide mutation rate of HIV-1, l, has been
estimated to be ¨2.5  105 per nucleotide per generation in
vitro (Mansky, 1996). Suppose that mutations occur with equal
probability among all four nucleotides and that the four
nucleotides occur with equal frequency. If only one amino
acid site is involved in the mutational escape of an epitope, a
nonzero advantageous mutation rate, ladv, for the epitope will
be between l/3 and 3l. If mutations at multiple sites in an
epitope can lead to escape, ladv of the epitope can be larger.
The kinetics of appearance of a mutant is strongly affected
by the effective population size (Fig. 2A). For Ne of the order
of 103, random drift plays an important role. The time required
to observe advantageous mutants is largely determined by theFig. 1. Schematic representation of the frequency dynamics of an advantageous
mutant. Some of these mutations will be lost due to stochastic forces (illustrated
here by lines not reaching a 0.01 frequency). tadv is the time required for the
occurrence of an advantageous mutant that accumulates and eventually
becomes fixed (Madv). t50% is the time after infection required for an
advantageous mutant to expand to compose 50% of the population. t100% is
the time after infection required for an advantageous mutant to become fixed.waiting time for the occurrence of an advantageous mutation
that eventually becomes fixed, tadv. For an amino acid site of
HIV-1 with an advantageous mutation rate of ladv = l/3, and a
selection coefficient of s = 0.1, over half of the time for the
Madv to reach 50% (t50%), is taken by tadv. For N (=Ne) = 10
3,
t50% ranged from ¨100 to over 10
3 generations, with a median
of 511, or about 2 years, given estimates for the HIV-1
generation time ranging from 1.2 to 2.6 days (Fu, 2001;
Markowitz et al., 2003; Mittler et al., 1999; Perelson et al.,
1996; Rodrigo et al., 1999). When N (=Ne) = 5  103, the
median t50% declined to 170 generations. For a very large
population of N (=Ne) = 10
5, advantageous mutations occur
almost every generation. In this case, evolution is largely
deterministic (Rouzine and Coffin, 1999) and the time required
for Madv to occur contributes little to tf. For N (=Ne) = 10
5 and
an amino acid site of HIV-1 with ladv = l/3 and s = 0.1, the
waiting time for Madv to appear was just a few days, and it took
about half a year for the advantageous mutant to reach a
frequency of 50%.
Mutation and selection also affect the appearance of
advantageous mutants (Fig. 2B). Random drift exerts stronger
effects when advantageous mutation rates and selection
coefficients are low. For N (=Ne) = 10
3 and an amino acid
site of HIV-1 with s = 0.01, the range of t50% was 198 to ¨10
6
generations (median = 5808) for ladv = l/3, and 183 to ¨10
3
generations (median = 876) for ladv = 3A. On the other hand,
for a site with s = 0.5, the range of t50% was 20 to 845
generations (median = 169) for ladv = l/3, and 15 to 144
generations (median = 34) for ladv = 3A. Although t50% is a
nonlinear function of l, s, and Ne, for the specific combination
of parameters Ne = 10
3, ladv = l/3, l = 2.5  105, and s =
0.1, 5-fold increases in s, ladv, and Ne all decreased medium
t50% by about the same amount (3.02, 3.4, and 3.01,
respectively).
The probability of observing advantageous mutants over time
using standard sampling techniques
Here, we consider cases in which only one amino acid site is
under positive selection. To estimate this probability in
populations of N (=Ne) = 10
3, we conducted forward
simulations with 10 viral sequences sampled at a time, as is
commonly done in viral evolution studies. As shown in Figs.
3A and B, advantageous mutants can emerge rapidly. For sites
with ladv = 3A and s  0.01, or sites with ladv = l/3 and s 
0.1, it is not unusual (>5% likelihood) to observe at least one
(10%) advantageous mutant within 100 generations (¨0.5
year) after infection. However, after 500 generations, about 2
years of infection, an advantageous mutant with ladv = l/3 and
s = 0.5 still has a 10% chance of remaining undetected. For an
advantageous amino acid mutant with ladv = l/3 and s = 0.1,
the chance of remaining undetected is 5.5%, even after 2000
generations (¨10 years of infection).
For a very large N (=Ne) = 10
5, evolution is almost
deterministic and we could estimate this probability from
frequency changes obtained from our model (see Materials and
methods). As shown in Fig. 3C, with a sample size of 10, and
Fig. 2. The time, in generations, required for the occurrence of an advantageous HIV-1 mutation that is eventually fixed (tadv), and to reach 50% (t50%) level in the
population after infection. (A) tadv and t50% for advantageous mutants at one amino acid site under positive selection with ladv = l/3 (l = 2.5 105); s = 0.1; and N =
103, 2 103, 3 103, 4 103, 5 103, 104, or 105. (B) tadv and t50% for advantageous mutants at one amino acid site under positive selection with N = 103, ladv = l/3
or 3l; and s = 0.01, 0.1, or 0.5. Bars and boxes give the minimum, the 25th percentile, the median, the 75th percentile, and the maximum, out of 100 replicates.
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probability of observing an advantageous mutant increases
rapidly over time. However, before 100 generations have
elapsed (¨0.5 years of infection), the probability of observing
over five advantageous mutants in a sample of 10 (50%) is
less than 70%. For an amino acid site with ladv = l/3 and s =
0.01, out of 10 samples, the probability of observing no
advantageous mutants within 400 generations (¨2 years) is
over 50%.
The effect of competition between multiple advantageous
mutants
The accumulation of one advantageous mutant can be
suppressed by other competing advantageous mutants, espe-
cially when other mutants have higher fitness (Gerrish and
Lenski, 1998; Kim and Stephan, 2003; Miralles et al., 1999),
although this may be relaxed by frequent recombination in
HIV-1 (Shriner et al., 2004a; Zhuang et al., 2002). To evaluate
this suppressive effect (known as clonal interference), we
performed simulations with six linked amino acid sites under
positive selection, each having ladv = l/3. The CTL escape
mutant was given s = 0.1, while each of the other five
competing sites was given s = 0.2. For N = 103, the probability
of observing no advantageous mutants at the site of interest
within the first 2000 generations increases from 5.5% in the
absence of competing mutants to 15% with five other sites
under stronger positive selection (Fig. 4A). For N = 105, within
the first 300 generations, we observed no advantageousmutants at the site of interest in 60% (12 out of 20) of our
simulations.
Discussion
The selective advantage of a CTL escape mutant of HIV-1 is
determined by the balance between the beneficial effect of
evading the corresponding CTL responses and the fitness costs
associated with having an altered protein. When the antiviral
effect of the corresponding CTL response is insignificant, the
advantage of escape is low. Alternatively, when an escape
mutation disrupts the key structure or function of the virus, it
can impose a replication fitness cost that may exceed the
benefit of escaping the CTL response. Small antiviral effects
and high fitness costs, therefore, can delay or prevent the
emergence of CTL escape mutants. Emergence of these
mutants can also be delayed by stochastic forces, such as
mutational bottlenecks, genetic drift, and competition from
other advantageous mutants in the population. However, these
forces are rarely mentioned when discussing the failure to
observe CTL escape mutants in vivo. In this study, we showed
that, with the best available estimates of effective population
size in chronically infected patients (¨103), the time to
appearance of selectively advantageous HIV-1 CTL escape
mutant(s) in chronically infected patients can be several years,
even with strong selective pressure.
We used published estimates for Ne and l as the starting
point for our investigations. For Ne = 10
3, ladv = l/3, l = 2.5
105, and s = 0.1, we found that 5-fold increases in Ne, the
Fig. 3. Probability of observing at least one (10%), at least five (50%), and all (100%) advantageous mutants over time, with a sample size of 10. (A) Probability
of observing advantageous mutants at one amino acid site under positive selection with N = 103; ladv = l/3; and s = 0.01, 0.1, or 0.5. (B) Probability of observing
advantageous mutants at one amino acid site under positive selection with N = 103; ladv = 3l; and s = 0.01, 0.1, or 0.5. (C) Probability of observing advantageous
mutants at one amino acid site under positive selection with N = 105; ladv = l/3 and s = 0.01 or 0.1.
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the mutant, s, all decrease the evolutionary time for escape
mutants to be detected by comparable amounts (¨3-fold),
though for larger values of Ne s has a bigger effect on t50% than
l (Coffin, 1995). Although most studies (Achaz et al., 2004;
Brown, 1997; Seo et al., 2002; Shriner et al., 2004b) suggest
that Ne ¨ 10
3, Rouzine and Coffin (1999) have estimated Ne to
be ¨105. However, Shriner et al. (2004b) have argued that
Rouzine and Coffin’s estimate of Ne is¨35-fold too high due to
a biased sampling procedure and the incorporation of an
incorrect mutation rate. Nonetheless, even with Ne = 10
5, an
advantageous mutant with s = 0.1 will still take about 100
generations (¨0.5 year) to reach a frequency of 50%.
We note that all of the estimates of Ne are based on
sequences obtained from chronically infected patients. In
primary infection, Ne for HIV-1 is likely to be much highersince these patients often have very high viral loads and a large
pool of CD4+ T-lymphocyte target cells (Mehandru et al.,
2004). Given the strong dependence of t50% on Ne, our model
suggests that escape mutants of CTL epitopes recognized
during primary infection can rise rapidly in patients. However,
many epitopes are recognized during chronic infection.
Because viral loads decline following the resolution of the
primary infection, the absolute number of viruses carrying
advantageous mutants that are not immediately selected will
decline as primary infection resolves. These mutants can
subsequently be lost due to drift during the chronic phase of
infection.
Another criticism of estimates of Ne ¨ 10
3 is that it may be
inappropriate to apply neutral models to populations that are
subject to strong selection. For example, it is possible that these
estimates of Ne are low because recurrent selection periodically
Fig. 4. Effect of additional selected sites on the probability of observing at least one (10%), at least five (50%), and all 10 (100%) mutants at a site of interest,
assuming a sample size of 10 and n additional selected sites. Here, ladv = l/3, s = 0.1 for the mutant of interest, and s = 0.2 for the other advantageous mutants. (A)
N = 103; (B) N = 105.
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recurrent selective sweeps are artificially reducing estimates
for Ne, one would still need to account for these sweeps when
calculating the time to appearance of a CTL escape mutant.
Our simulations show that even with a simulated population
size of N = 105 that a moderately advantageous escape mutant
(s = 0.1) may still take ¨2 years to be detected if it has to
compete with other more advantageous mutants. Thus,
potential errors in the calculation or interpretation of Ne due
to selection do not necessarily mean that the times to
appearance of CTL escape mutants will be short.
Our model also assumes constant population size, no
subdivision, discrete generations, no latent infection, constant
selection, no recombination, and no dual or superinfection.
Population fluctuations and subdivision generally reduce
effective population sizes, which would most likely lead to
even longer delay times. Violation of discrete generations and
no latently infected cells are unlikely to have a large effect on
our calculations since HIV-1 turns over rapidly (Liu et al.,
2004; Ramratnam et al., 1999) and because viral production of
latently infected cells were minimum compared to productively
infected cells. Violation of the constant selection assumption is
neutral with respect to our argument: depending on how the
selection coefficient changed over time, delay times would
change accordingly. Although dual or superinfection could
reduce delay times by increasing genetic diversity, only a small
proportion of HIV-1 patients are thought to be infected with
multiple HIV-1 strains. If recombination rates are high, the
delay times given in Fig. 4 would decrease. However, our other
results will not be affected by recombination since they focus
on only a single locus.In this study, we only examined advantageous mutants
requiring a single nucleotide mutation. For advantageous
mutants that require multiple nucleotide mutations to escape
or compensatory mutations at other amino acid sites to maintain
fitness, the time required for observation will be even longer. In
addition, during HIV-1 infection, multiple amino acid sites can
be under different selection pressures simultaneously. For
example, it is not unusual to observe multiple epitopes eliciting
CTL responses at the same time (Cao et al., 2003; Goulder et al.,
2001). As discussed above, our results suggest that competition
from other advantageous mutants may also delay the observa-
tion of the mutant of interest.
In summary, researchers studying the selective pressures
attributable to CTL should not only carefully evaluate the
antiviral effect of CTL responses and fitness constraints at CTL
epitopes, but also consider the effect of stochastic evolutionary
forces on the appearance of escape mutants. Failure to
immediately observe CTL escape mutants does not necessarily
indicate that CTL is not exerting effects in vivo. While we have
focused our efforts on HIV-1 in response to a perceived
problem in interpreting CTL escape data, these models are very
general: similar delays could occur for other infectious diseases
and other kinds of advantageous mutants.
Materials and methods
Estimation of the time required for an HIV-1 advantageous
mutant to reach a given frequency
To estimate this time, we conducted forward simulations
(Liu et al., 2004), using a Wright–Fisher model (Wright,
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subdivision, constant selection, discrete generations, no
recombination, no latent infection, and no dual or superin-
fection. Estimates for the effective population size for HIV-1
in untreated patients, Ne, range from ¨10
3 (Achaz et al.,
2004; Brown, 1997; Seo et al., 2002; Shriner et al., 2004b) to
¨105 (Frost et al., 2000; Rouzine and Coffin, 1999). The in
vivo advantageous mutation rate, ladv, is related to the
average in vivo nucleotide mutation rate, l, which we assume
is equal to in vitro estimates of ¨2.5  105 mutations per
nucleotide per generation (Mansky, 1996). For simplicity, we
assume that any nucleotide can mutate to the other three
nucleotides with equal probability and that each site has the
same underlying mutation rate, l. With these assumptions,
the rate of mutation to a particular nucleotide will be l/3. For
a randomly chosen codon, following the genetic code, if
mutations at only one amino acid site in an epitope can lead
to escape, a nonzero ladv for the epitope will be between l/3
and 3l. Therefore, we simulated initially homogeneous
populations with N = 103, 2  103, 3  103, 4  103,
5  103, 104, or 105; ladv = l/3 or 3l (l = 2.5  105); and
s = 0.01, 0.1, or 0.5. Frequency changes of the advantageous
mutants over time were recorded. One hundred replicates
were simulated.
Estimation of the probability of observing advantageous
mutants over time
For small effective population sizes, random drift is
important for the rise in frequency of advantageous mutants.
To quantify the probability of observing advantageous amino
acid changes over time, we conducted forward simulations with
initially homogeneous population of N = 103 and l = 2.5 
105. One amino acid site was under positive selection, with
ladv = l/3 or 3l, and s = 0.01, 0.1, or 0.5. Ten samples were
collected at generations 100, 200, 500, 1000, and 2000. One
thousand replicates were simulated. For a very large population
of N = 105, evolution is almost deterministic and the
probability of observing advantageous amino acid changes is
calculated according to the frequency changes of the advanta-
geous mutants over time, generated by simulations described
above. With a sample size of 10, the probability of observing n
(0  n  10) advantageous mutants of a given f can be
calculated according to a binomial distribution:
p10 nð Þ ¼ 10
n

 f n  1 fð Þ10n:
Effect of competition between multiple advantageous mutants
Forward simulations were performed with initially homo-
geneous population of N = 103 or 105 and l = 2.5  105. Six
linked amino acid sites were under positive selection, each with
ladv = l/3. The site of interest had s = 0.1 and each of the other
five competing sites had s = 0.2. The gain of fitness was
additive. For N = 103, 10 samples were collected at generations
100, 200, 500, 1000, and 2000. One thousand replicates weresimulated. For N = 105, 10 samples were collected at
generations 100, 200, 300, 400, and 500. Twenty replicates
were simulated.
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